62 related articles for article (PubMed ID: 37144107)
1. Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient.
Aldecoa KAT; Macaraeg CSL; Dadlani A; Yadlapalli S
Case Rep Hematol; 2023; 2023():1691996. PubMed ID: 38130705
[TBL] [Abstract][Full Text] [Related]
2. Comparative Analysis of Risk Prediction Scores for Treatment-Emergent Atrial Fibrillation Among Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
Babbili A; Lakra R; Thotamgari SR; Gaddam SJ; Grewal US; Dominic P
Am J Ther; 2024 Feb; ():. PubMed ID: 38305826
[No Abstract] [Full Text] [Related]
3. Tranexamic Acid for Postoperative Bleeding in a Patient Treated With Ibrutinib.
Algarra-Sahuquillo J; Pestana-Eliche M; Markthaler M; Martín-Neda FG
Dermatol Surg; 2024 Jun; ():. PubMed ID: 38833410
[No Abstract] [Full Text] [Related]
4. Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia:
Quartermaine C; Ghazi SM; Yasin A; Awan FT; Fradley M; Wiczer T; Kalathoor S; Ferdousi M; Krishan S; Habib A; Shaaban A; Kola-Kehinde O; Kittai AS; Rogers KA; Grever M; Ruz P; Bhat S; Dickerson T; Byrd JC; Woyach J; Addison D
JACC CardioOncol; 2023 Oct; 5(5):570-590. PubMed ID: 37969643
[TBL] [Abstract][Full Text] [Related]
5. The risk vs. benefit calculus of anticoagulation in patients with ibrutinib-related atrial fibrillation.
Patel R; Singh A; Meng Z; Baldridge AS; Addison D; Akhter N
Leuk Lymphoma; 2024 Feb; 65(2):168-174. PubMed ID: 37953609
[TBL] [Abstract][Full Text] [Related]
6. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
[TBL] [Abstract][Full Text] [Related]
7. Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Wang J; Zhao A; Zhou H; Zhu J; Niu T
Front Pharmacol; 2020; 11():580622. PubMed ID: 33658926
[No Abstract] [Full Text] [Related]
8. Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients.
Diamond A; Bensken WP; Vu L; Dong W; Koroukian SM; Caimi P
JACC CardioOncol; 2023 Apr; 5(2):233-243. PubMed ID: 37144107
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
Abdel-Qadir H; Sabrie N; Leong D; Pang A; Austin PC; Prica A; Nanthakumar K; Calvillo-Argüelles O; Lee DS; Thavendiranathan P
J Clin Oncol; 2021 Nov; 39(31):3453-3462. PubMed ID: 34464154
[TBL] [Abstract][Full Text] [Related]
10. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891
[TBL] [Abstract][Full Text] [Related]
11. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
12. Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans Health Administration.
Rasmussen KM; Patil V; Burningham Z; Yong C; Sauer BC; Halwani AS
Fed Pract; 2020 May; 37(Suppl 2):S44-S49. PubMed ID: 32952387
[TBL] [Abstract][Full Text] [Related]
13. High incidence of atrial fibrillation in patients treated with ibrutinib.
Baptiste F; Cautela J; Ancedy Y; Resseguier N; Aurran T; Farnault L; Escudier M; Ammar C; Gaubert M; Dolladille C; Barraud J; Peyrol M; Cohen A; Paganelli F; Alexandre J; Ederhy S; Thuny F
Open Heart; 2019; 6(1):e001049. PubMed ID: 31168393
[TBL] [Abstract][Full Text] [Related]
14. Better prediction of stroke in atrial fibrillation with incorporation of cancer in CHA
Bungo B; Chaudhury P; Arustamyan M; Rikhi R; Hussain M; Collier P; Kanj M; Khorana AA; Mentias A; Moudgil R
Int J Cardiol Heart Vasc; 2022 Aug; 41():101072. PubMed ID: 35757148
[TBL] [Abstract][Full Text] [Related]
15. Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib.
Avalon JC; Fuqua J; Miller T; Deskins S; Wakefield C; King A; Inderbitzin-Brooks S; Bianco C; Veltri L; Fang W; Craig M; Kanate A; Ross K; Malla M; Patel B
Cardiooncology; 2021 Nov; 7(1):38. PubMed ID: 34798905
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
